Cargando…

Targeting M2 Macrophages with a Novel NADPH Oxidase Inhibitor

ROS in cancer cells play a key role in pathways regulating cell death, stemness maintenance, and metabolic reprogramming, all of which have been implicated in resistance to chemo/ immunotherapy. Adjusting ROS levels to reverse the resistance of cancer cells without impairing normal cell functions is...

Descripción completa

Detalles Bibliográficos
Autores principales: Dilly, Sébastien, Romero, Miguel, Solier, Stéphanie, Feron, Olivier, Dessy, Chantal, Slama Schwok, Anny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951936/
https://www.ncbi.nlm.nih.gov/pubmed/36830003
http://dx.doi.org/10.3390/antiox12020440
_version_ 1784893504401440768
author Dilly, Sébastien
Romero, Miguel
Solier, Stéphanie
Feron, Olivier
Dessy, Chantal
Slama Schwok, Anny
author_facet Dilly, Sébastien
Romero, Miguel
Solier, Stéphanie
Feron, Olivier
Dessy, Chantal
Slama Schwok, Anny
author_sort Dilly, Sébastien
collection PubMed
description ROS in cancer cells play a key role in pathways regulating cell death, stemness maintenance, and metabolic reprogramming, all of which have been implicated in resistance to chemo/ immunotherapy. Adjusting ROS levels to reverse the resistance of cancer cells without impairing normal cell functions is a new therapeutic avenue. In this paper, we describe new inhibitors of NADPH oxidase (NOX), a key enzyme in many cells of the tumor microenvironment. The first inhibitor, called Nanoshutter-1, NS1, decreased the level of tumor-promoting “M2” macrophages differentiated from human blood monocytes. NS1 disrupted the active NADPH oxidase-2 (NOX2) complex at the membrane and in the mitochondria of the macrophages, as shown by confocal microscopy. As one of the characteristics of tumor invasion is hypoxia, we tested whether NS1 would affect vascular reactivity by reducing ROS or NO levels in wire and pressure myograph experiments on isolated blood vessels. The results show that NS1 vasodilated blood vessels and would likely reduce hypoxia. Finally, as both NOX2 and NOX4 are key proteins in tumors and their microenvironment, we investigated whether NS1 would probe these proteins differently. Models of NOX2 and NOX4 were generated by homology modeling, showing structural differences at their C-terminal NADPH site, in particular in their last Phe. Thus, the NADPH site presents an unexploited chemical space for addressing ligand specificity, which we exploited to design a novel NOX2-specific inhibitor targeting variable NOX2 residues. With the proper smart vehicle to target specific cells of the microenvironment as TAMs, NOX2-specific inhibitors could open the way to new precision therapies.
format Online
Article
Text
id pubmed-9951936
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99519362023-02-25 Targeting M2 Macrophages with a Novel NADPH Oxidase Inhibitor Dilly, Sébastien Romero, Miguel Solier, Stéphanie Feron, Olivier Dessy, Chantal Slama Schwok, Anny Antioxidants (Basel) Article ROS in cancer cells play a key role in pathways regulating cell death, stemness maintenance, and metabolic reprogramming, all of which have been implicated in resistance to chemo/ immunotherapy. Adjusting ROS levels to reverse the resistance of cancer cells without impairing normal cell functions is a new therapeutic avenue. In this paper, we describe new inhibitors of NADPH oxidase (NOX), a key enzyme in many cells of the tumor microenvironment. The first inhibitor, called Nanoshutter-1, NS1, decreased the level of tumor-promoting “M2” macrophages differentiated from human blood monocytes. NS1 disrupted the active NADPH oxidase-2 (NOX2) complex at the membrane and in the mitochondria of the macrophages, as shown by confocal microscopy. As one of the characteristics of tumor invasion is hypoxia, we tested whether NS1 would affect vascular reactivity by reducing ROS or NO levels in wire and pressure myograph experiments on isolated blood vessels. The results show that NS1 vasodilated blood vessels and would likely reduce hypoxia. Finally, as both NOX2 and NOX4 are key proteins in tumors and their microenvironment, we investigated whether NS1 would probe these proteins differently. Models of NOX2 and NOX4 were generated by homology modeling, showing structural differences at their C-terminal NADPH site, in particular in their last Phe. Thus, the NADPH site presents an unexploited chemical space for addressing ligand specificity, which we exploited to design a novel NOX2-specific inhibitor targeting variable NOX2 residues. With the proper smart vehicle to target specific cells of the microenvironment as TAMs, NOX2-specific inhibitors could open the way to new precision therapies. MDPI 2023-02-10 /pmc/articles/PMC9951936/ /pubmed/36830003 http://dx.doi.org/10.3390/antiox12020440 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dilly, Sébastien
Romero, Miguel
Solier, Stéphanie
Feron, Olivier
Dessy, Chantal
Slama Schwok, Anny
Targeting M2 Macrophages with a Novel NADPH Oxidase Inhibitor
title Targeting M2 Macrophages with a Novel NADPH Oxidase Inhibitor
title_full Targeting M2 Macrophages with a Novel NADPH Oxidase Inhibitor
title_fullStr Targeting M2 Macrophages with a Novel NADPH Oxidase Inhibitor
title_full_unstemmed Targeting M2 Macrophages with a Novel NADPH Oxidase Inhibitor
title_short Targeting M2 Macrophages with a Novel NADPH Oxidase Inhibitor
title_sort targeting m2 macrophages with a novel nadph oxidase inhibitor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951936/
https://www.ncbi.nlm.nih.gov/pubmed/36830003
http://dx.doi.org/10.3390/antiox12020440
work_keys_str_mv AT dillysebastien targetingm2macrophageswithanovelnadphoxidaseinhibitor
AT romeromiguel targetingm2macrophageswithanovelnadphoxidaseinhibitor
AT solierstephanie targetingm2macrophageswithanovelnadphoxidaseinhibitor
AT feronolivier targetingm2macrophageswithanovelnadphoxidaseinhibitor
AT dessychantal targetingm2macrophageswithanovelnadphoxidaseinhibitor
AT slamaschwokanny targetingm2macrophageswithanovelnadphoxidaseinhibitor